List of Vaccines Companies in Pennsylvania - 16

Specialty oncology-focused biopharmaceutical company based in Malvern, PA with a broad pipeline encompassing novel best in class selective HDAC6i immunomodulators and a game changing myeloid based discovery platform. Avstera focuses on foundational tumor biology science, while methodologically breaking barriers using cutting-edge approaches in order to deliver impactful treatments to cancer patients.

A small, agile CRO. The primary function of the scientists at BioAnalysis, LLC is to provide a collaborative workspace that enables productive and effective solutions to the client’s problems. The traditional CRO model works well, however, at BioAnalysis, LLC we believe that collaborative interactions, communication and robust experimental design along with gold-standard quality results are the true value-added. The scientists of BioAnalysis, LLC possess a wealth of experience in characterization of therapeutic proteins, mAbs, and ADC (DARs), non-biologics (Polymers, PEO/PLA, nanoparticles), ICH/FDA regulatory applications, process development, and assessment of final biologic product formulations. Our subject matter expertise in the areas of Biophysics and Proteomics is showcased in over 70 peer reviewed publications.

Chimeron Bio is a biotechnology company focused on developing personalized gene therapies, including self-amplifying RNA vaccines and therapeutics designed on its proprietary technology.

At Geneos, our passion is to develop personalized therapies to unleash the most powerful force against cancer – your body’s own immune system. Our GT-EPIC Platform is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor specific neoantigen-targeted personalized immunotherapies.

INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from serious and life-threatening diseases associated with HPV, cancer, and infectious diseases.

Integral Molecular is a research-driven biotechnology company specializing in antibodies, viruses, and membrane proteins. We develop technologies for solving big scientific challenges and advancing therapies against difficult-to-treat diseases. Our products, platforms, and services enable antibody discovery, biotherapeutic safety profiling, vaccine development, protein engineering, and more. Learn why top pharmaceutical and biotechnology companies trust Integral Molecular. Instagram: IntegralMolecular

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus' natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir's cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh's world-class oncolytic virus and immunotherapy research programs.

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called “immunotherapy”. Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications. Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity. Since the company’s inception, the founders have been responsible for funding the development of the IMT504 technology platform, investing over $23M to date. They continue to invest in this promising new therapy to develop therapies to impact disease with innovative treatments.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.

Polysciences introduces Kyfora Bio, our bioprocessing brand, supporting development of cell and gene therapy (CGT) breakthroughs from bench to clinic. Backed by 60+ years of specialty chemical development, manufacturing, and application expertise, Kyfora provides research grade through cGMP transfection reagents and excipients for viral vectors, mRNA vaccines, and other drug delivery applications. Our cost-effective and scalable cGMP processes empower advanced therapies to improve patient lives.

PPD is part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and its PPD clinical research business are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We offer a comprehensive suite of world-class services across the clinical development spectrum – from scientific discovery, to assessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of the drug product.

Rockland Antibodies is a biotechnology company that offers a wide range of antibodies for academic, biopharma, and diagnostic professionals, catering to various research and development needs.

Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.

The Wistar Institute is a biomedical research institution that focuses on advancing knowledge in life sciences and medical research.

Thomas Jefferson University is a private university in Philadelphia, Pennsylvania. Established in its earliest form in 1824, the university officially combined with Philadelphia University in 2017.

Tunnell Consulting is a consulting firm that specializes in providing operational and strategic services to the life sciences, healthcare, pharmaceutical, and biotechnology industries with a focus on regulatory compliance.